Successful omalizumab treatment in chronic spontaneous urticaria is associated with lowering of serum IL-31 levels.

Altrichter, S; Hawro, T; Hänel, K; Czaja, K; Lüscher, B; Maurer, M; Church, M K; Baron, J M

Altrichter, S; Hawro, T; Hänel, K; Czaja, K; Lüscher, B; Maurer, M; Church, M K; Baron, J M.

Afiliação

Altrichter S; Department of Dermatology and Allergology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Hawro T; Department of Dermatology and Allergology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Hänel K; Department of Dermatology and Allergology, Medical School RWTH Aachen University, Aachen, Germany.
Czaja K; Medical School RWTH Aachen University, Institute of Biochemistry and Molecular Biology, Aachen, Germany.
Lüscher B; Department of Dermatology and Allergology, Medical School RWTH Aachen University, Aachen, Germany.
Maurer M; Medical School RWTH Aachen University, Institute of Biochemistry and Molecular Biology, Aachen, Germany.
Church MK; Department of Dermatology and Allergology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Baron JM; Department of Dermatology and Allergology, Charité - Universitätsmedizin Berlin, Berlin, Germany.

J Eur Acad Dermatol Venereol ; 30(3): 454-5, 2016 Mar.

Article em En | MEDLINE | ID: mdl-25371135

Assuntos

Interleucinas/sangue; Omalizumab/administração & dosagem; Pele/patologia; Urticária/tratamento farmacológico; Antialérgicos/administração & dosagem; Biomarcadores/sangue; Doença Crônica; Seguimentos; Humanos; Injeções Subcutâneas; Urticária/sangue; Urticária/diagnóstico

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pele / Urticária / Interleucinas / Omalizumab Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies Limite: Humans Idioma: En Revista: J Eur Acad Dermatol Venereol Ano de publicação: 2016 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google